Page 3 - Laurus Lab News Today

ImmunoACT has portfolio of Chimeric Antigen Receptor T cells (CAR-T cells) therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications.

Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86% on fully diluted basis.

Based on the OI percentage, 56 stocks were on the short-covering list. These included Balkrishna Industries, Divis Laboratories, Dabur India, Nestle India, and Britannia Industries.

Laurus Labs Ltd announced today that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited.

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 340 in its research report dated April 27, 2023.

Laurus Labs on Monday posted a 32 per cent growth year-on-year to Rs 203 crore. The pharmaceutical firm revenue went up 50 per cent y-o-y to Rs 1,545 crore wh

Laurus Labs on Monday posted a 32 per cent growth year-on-year to Rs 203 crore

The scrip fell 5.69 per cent to a low of Rs 452.45 on BSE. With this, the scrip has fallen 14.39 per cent in three trading sessions.

The scrip fell 7.34 per cent to close the day at Rs 487.45 on BSE, taking its year-to-date fall to 9.79 per cent. 

Laurus Labs’ (Laurus) Q1FY22-23 results instilled confidence in investors regarding its target of achieving US$1bn (billion) in sales in FY22-23